On the clinical front line of cardiology, a thorny dilemma has always plagued doctors and patients: when faced with high-risk PCI surgery, acute cardiogenic shock, and other critical illnesses, traditional circulatory support equipment is either "insufficient" or "too traumatic". And now, MoyoAssist from Xinqing Medical ® The Extra VAD extracorporeal magnetic levitation ventricular assist system - a national innovative product, is redefining the standards of critical care in cardiology with its core advantages of "precision, minimally invasive, efficient, and economical", and opening a door to a billion dollar market for cardiac agents. Especially in the current centralized procurement environment of intracardiac consumables, it is even more urgent to have new surgical products.
1、 Urgent clinical pain points and explosive market demand: Opportunities for agents
The 'essential need' in the field of critical care in cardiology has long been an open industry pain point.
In high-risk coronary intervention (PCI) surgery, traditional IABP equipment has limited circulatory support, which often makes it difficult to stabilize patient hemodynamics in complex cases such as severe occlusion of three blood vessels; Although ECMO provides strong support, it may increase intracardiac shunting and cause complications such as limb ischemia and massive bleeding. The case of the First People's Hospital of Yunnan Province is enough to illustrate the problem: a 38 year old patient with three vessel occlusion successfully completed high-risk PCI with the support of Extra VAD, and was able to move around on the ground 4 days after surgery, leaving only three 4mm minimally invasive wounds - this clinical effect has made doctors exclaim that it "overturns cognition".
Looking at acute cardiogenic shock again: Patients with myocardial infarction and ventricular septal perforation experience increased cardiac load due to shunting every minute and second, and traditional equipment often fails to stabilize circulation in time. Extra VAD can quickly implement left ventricular decompression, reduce shunt at the puncture site, and strive for a critical window period for surgical procedures. Harbin Medical University Second Hospital once used it to provide 8-day support for patients with ventricular septal perforation after myocardial infarction, and the surgery was ultimately successful. Such cases are rapidly being replicated nationwide.
For agents, this means an unmet blue ocean market: the number of critically ill patients in cardiology is increasing year by year, and there are few devices that can simultaneously address both "support" and "safety". The emergence of Extra VAD has precisely filled this gap, and the outbreak of market demand is only a matter of time.
2、 High technological barriers, crushing competitive advantages: a promotional tool for agents
A product that allows doctors to actively choose must have its' irreplaceability '. The technological advantage of Extra VAD is the strongest promotional confidence for agents.
The full magnetic levitation technology is its core barrier. By adopting a 'zero contact impeller design', the risk of blood damage is fundamentally reduced - the incidence of complications such as hemolysis and thrombosis is much lower than traditional equipment, and the longest support time can reach 30 days, which means it can cover the full scenario needs from short-term emergency to mid-term transition. More importantly, the "precise flow control" function can automatically adjust the auxiliary flow according to the patient's real-time condition, just like equipping the heart with an "intelligent assistant". In the Yunnan case, the patient was able to recover quickly, and this technology is indispensable.
Minimally invasive procedures directly address clinical pain points. Only percutaneous puncture (such as axillary artery and femoral artery access) is required, with a maximum incision of only 4 millimeters, and the operation time is reduced by more than half compared to ECMO, fully meeting the "fast response" needs of cardiology catheterization rooms. In contrast, ECMO requires a large incision in the femoral artery and vein, which poses a high risk of infection and limb ischemia, and requires collaboration among multiple departments. On the other hand, the Extra VAD cardiology team can operate independently, greatly reducing the clinical application threshold.
The advantage of this "technology crushing level" has made Extra VAD an unshakable competitive advantage among similar products. For agents, promoting a product that is recognized by doctors, easy to operate, and has significant effects will undoubtedly be twice the result with half the effort.
3、 Clear economic accounts and policy dividends: profit guarantee for agents
For agents, the "profit margin" and "accessibility" of products are crucial. Extra VAD has significant advantages in both aspects.
The cost advantage is visible to the naked eye. The document clearly states that its cost is significantly lower than ECMO, and as a domestically produced equipment, the procurement and maintenance costs are much lower than imported products. This means that the acceptance of hospitals is higher - it can reduce the burden on patients and control departmental costs, especially suitable for the popularization of secondary and above hospitals. At the same time, it focuses on "short - to medium-term support", avoiding the high cost of long-term ventricular assist devices and perfectly meeting the needs of "transitional treatment" (such as waiting for heart transplantation and heart function recovery), further expanding its applicability.
Policy dividends provide even more assistance. As the first domestically approved fully magnetic levitation external VAD, Extra VAD fully aligns with the national policy of "domestic substitution of high-end medical devices". As a national level innovative medical device, it has been included in medical insurance in various regions, and the expansion of medical insurance coverage in the future will be an inevitable trend. For agents, a product with policy support and strong adaptability to medical insurance will significantly reduce promotion resistance and shorten the profit cycle.
The combination of controllable costs, policy support, and high market demand makes the profit model of Extra VAD clearly visible. Agents do not need to worry about whether they will be well received or not, as long as they enter the market, they can quickly form a stable revenue stream.
4、 Multi scenario full coverage, broad cooperation boundaries: market increment for agents
The 'market ceiling' of a product depends on the breadth of its application scenarios. The multi scenario coverage capability of Extra VAD expands infinite possibilities for agents.
On the "Application Scenario Table", it can cover multiple core cardiology scenarios such as cardiogenic shock, heart failure transition support, intraoperative protection for severe PCI, and postoperative low cardiac output syndrome:
• During cardiogenic shock, rapid and stable circulation can buy time for etiological treatment;
• Severe PCI intraoperative protection helps to avoid thoracotomy during complex and high-risk PCI surgeries, which can be performed directly in the catheterization room;
• When heart failure patients are waiting for transplantation, it acts as a "bridge" to reduce the mortality rate during the waiting period;
• During low cardiac output after cardiac surgery, assist in removing from extracorporeal circulation to accelerate cardiac function recovery.
More importantly, it is also a 'link' for interdisciplinary collaboration. After implantation in the cardiology department, it can be connected to cardiac surgery and intensive care medical monitoring. This cross departmental linkage requirement allows the product to penetrate into multiple departments of the hospital system, not just limited to cardiology. For agents, this means that a single product can drive procurement from multiple departments, greatly expanding the market growth space.
5、 Manufacturers provide full support and grow together with agents: your backing is strong enough
Representing a product not only depends on the product itself, but also on the manufacturer's level of support. Xinqing Medical has already prepared a "comprehensive empowerment plan" for agents.
Clinical evidence continues to strengthen: Manufacturers will frequently output successful cases (such as high-risk PCI in Yunnan and treatment of ventricular septal perforation at Harbin Medical University), and provide authoritative clinical data (such as the "survival rate better than ECMO and lower complication rate" confirmed by Peking Union Medical College Hospital), so that agents can have a basis for promotion.
Standardized training system: Collaborate with benchmark hospitals such as Wuhan Union Medical College and Harbin Medical University Second Hospital to conduct operational training, develop standardized procedures for minimally invasive catheterization, help partner hospitals quickly master the technology, and reduce the "education cost" of agents.
Departmental benefit linkage support: Provide agents with a "cost reduction and efficiency improvement" calculation tool, visually demonstrate the value of "shortening ICU stay time and reducing total treatment costs" to hospital managers, and help agents connect the hospital decision-making chain.
The upgrade wave of critical care treatment in cardiology has arrived, and the Extra VAD of ASRock Medical is becoming a core player in this blue ocean market with its triple advantages of "clinical necessity+technical barriers+policy dividends". Now, we sincerely invite agents with foresight and resources to join us, share the dividends of the era of domestic high-end medical device replacement, and together bring safer and more efficient treatment solutions to millions of patients, maximizing commercial value while safeguarding life and health.